ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag us supreme court developmental biology disease medicine evolution

Short Shrift to Evolution?
Barry Palevitz and Ricki Lewis | Feb 1, 1999 | 7 min read
Editor's Note: In this essay, the authors--both scientists and writers--discuss recent news stories on evolution and express their opinions on how the stories were handled by the mainstream press. Evolution took center stage at the National Association of Biology Teachers (NABT) annual meeting in Reno, Nev., Nov. 3-8, 1998. If the teachers needed a theme, evolution was a logical choice--after all, it underlies and unifies contemporary biology. But NABT had other fish to fry. Despite a spate of c
An illustration of green bacteria floating above neutral-colored intestinal villi
The Inside Guide: The Gut Microbiome’s Role in Host Evolution
Catherine Offord | Jul 1, 2021 | 10+ min read
Bacteria that live in the digestive tracts of animals may influence the adaptive trajectories of their hosts.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Notebook
The Scientist Staff | Dec 7, 1997 | 7 min read
November was a rollercoaster month at the National Academy of Sciences (NAS). First, the United States Supreme Court declined to hear NASA's appeal of a lower court ruling subjecting the academy and its committees to the Federal Advisory Committees Act (FACA) of 1972. Animal rights groups argued that under FACA there should have been more public representation on a committee set up to revise the NIH Guide for the Care and Use of Laboratory Animals (R. Finn, The Scientist, July 22, 1996, page 1)
A Question of Chimeras
Clare Kittredge(ckittredge@the-scientist.com) | Apr 10, 2005 | 6 min read
Looking to cure a host of neurodegenerative diseases, StemCells, a Palo Alto, Calif.-based company, has transplanted human neural stem cells into the brains of thousands of mice.
Cloning Capsized?
Ted Agres | Aug 19, 2001 | 10+ min read
Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th
How to Create a Successful Fish Tale?
A. J. S. Rayl | Aug 19, 2001 | 10+ min read
More than 80 percent of the planet's living organisms exist only in aquatic ecosystems. Some may harbor secrets to human origins, and clues, treatments--perhaps even cures--for human disease. Some are critical bioindicators that portend the health of the biosphere. Yet, overall, scientists know little about the biochemical processes of these life forms. The vast, rich knowledge within the oceans and freshwater systems on Earth remains virtually untapped, because in the world of biological resear
The Biggest Stories in Bioscience 2005
Ishani Ganguli | Dec 4, 2005 | 8 min read
Life scientists have been challenged more than ever this year not just to critically analyze data, but to better interpret those data for an increasingly critical public.
Notebook
Eugene Russo | Dec 5, 1999 | 7 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria Notebook Pictured above are pigmented bacterial colonies of Deinococcus radiodurans, the most radiation-resistant organism currently known. DEINO-MITE CLEANUP In 1956, investigators discovered a potentially invaluable cleanup tool in an unlikely place. A hardy bacterium called Deinococcus radiodurans unexpectedly thrived in samples of canned meat thought to be sterilized by gamma radiation. The b
Notebook
The Scientist Staff | Apr 26, 1998 | 8 min read
WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

Run a Search

ADVERTISEMENT